VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viatris Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.26−0.39 (-2.12%)
Close on Oct 19, 2026
- Market cap
- $21.24B
- P/E (TTM)
- –
- Dividend yield
- 2.63%
Viatris Inc revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | $2.20B | $2.03B | $2.26B | $2.27B | $2.13B | $1.90B | $2.16B | $2.31B | $2.33B | $2.17B | $2.35B | $2.41B | 58.6% | +3.4% |
| Greater China | $713.80M | $680.10M | $572.90M | $615.20M | $588.90M | $555.50M | $522.30M | $562.20M | $539.40M | $543.90M | $515.30M | $548.40M | 19.0% | +21.2% |
| Emerging Markets Segment | $543.80M | $537.40M | $565.80M | $571.80M | $556.90M | $523.10M | $514.00M | $535.30M | $582.30M | $628.80M | $630.40M | $642.50M | 14.5% | -2.4% |
| Japan, Australia and New Zealand Segment | $296.20M | $273.50M | $306.60M | $307.30M | $306.70M | $277.10M | $336.30M | $345.50M | $349.80M | $318.10M | $373.40M | $334.50M | 7.9% | -3.4% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | $937.30M | $780.80M | – | $944.10M | $875.50M | $738.10M | – | $1.04B | $1.01B | $913.30M | $1.00B | $1.09B | +7.1% |
| Greater China | $509.50M | $497.30M | – | $416.80M | $401.80M | $384.70M | – | $362.20M | $349.40M | $366.30M | $328.20M | $354.60M | +26.8% |
| Emerging Markets Segment | $232.30M | $246.70M | – | $233.60M | $238.10M | $236.00M | – | $208.20M | $232.70M | $279.50M | $228.40M | $273.60M | -2.4% |
| Japan, Australia and New Zealand Segment | $76.30M | $64.70M | – | $70.20M | $83.70M | $62.20M | – | $102.90M | $101.30M | $87.30M | $135.40M | $125.40M | -8.8% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brands | $2.42B | $2.33B | $2.35B | $2.44B | $2.28B | $2.12B | $2.17B | $2.36B | $2.36B | $2.31B | $2.40B | $2.53B | 64.4% | +5.9% |
| Generics | $1.33B | $1.18B | $1.34B | $1.31B | $1.28B | $1.13B | $1.35B | $1.38B | $1.42B | $1.34B | $1.42B | $1.40B | 35.3% | +3.3% |
| Lipitor | $452.20M | $462.00M | $377.30M | $396.10M | $387.90M | $388.00M | $355.90M | $375.60M | $348.40M | $388.90M | $379.80M | $381.60M | 12.0% | +16.6% |
| Norvasc | $200.20M | $210.00M | $175.20M | $179.70M | $182.70M | $172.30M | $166.20M | $168.90M | $161.90M | $176.30M | $171.80M | $175.50M | 5.3% | +9.6% |
| EpiPen Auto-Injectors | $129.20M | $101.10M | $79.00M | $157.20M | $136.80M | $96.70M | $73.10M | $123.20M | $115.50M | $80.20M | $87.00M | $131.90M | 3.4% | -5.6% |
| Lyrica | $120.60M | $120.60M | $119.80M | $126.50M | $128.10M | $112.60M | $127.00M | $129.90M | $124.30M | $114.20M | $133.40M | $141.70M | 3.2% | -5.9% |
| Viagra | $112.90M | $95.00M | $104.20M | $105.20M | $100.30M | $98.50M | $88.60M | $100.20M | $106.10M | $100.70M | $92.30M | $110.50M | 3.0% | +12.6% |
| Creon | $97.40M | $97.40M | $98.90M | $93.10M | $91.40M | $82.40M | $90.40M | $84.60M | $78.20M | $75.00M | $80.60M | $77.50M | 2.6% | +6.6% |
| Celebrex | $76.40M | $67.10M | $66.20M | $73.30M | $70.00M | $63.40M | $67.10M | $74.10M | $72.20M | $72.20M | $75.10M | $84.70M | 2.0% | +9.1% |
| Zoloft | $71.40M | $72.60M | $66.80M | $66.80M | $61.10M | $60.20M | $58.20M | $60.60M | $58.90M | $58.00M | $62.00M | $62.70M | 1.9% | +16.9% |
| Yupelri | $70.70M | $62.50M | $70.60M | $71.40M | $66.60M | $58.30M | $66.60M | $62.20M | $54.50M | $55.20M | $60.50M | $58.30M | 1.9% | +6.2% |
| Effexor | $66.70M | $62.00M | $68.10M | $67.20M | $63.10M | $59.30M | $64.50M | $66.30M | $62.70M | $59.40M | $68.00M | $65.50M | 1.8% | +5.7% |
| Dymista | $39.80M | $37.30M | $38.60M | $33.80M | $48.40M | $42.80M | $41.30M | $43.50M | $55.00M | $48.20M | $45.00M | $44.10M | 1.1% | -17.8% |
| Amitiza | $39.40M | $34.00M | $42.40M | $40.80M | $41.60M | $33.30M | $41.10M | $38.20M | $36.90M | $33.00M | $41.20M | $37.70M | 1.0% | -5.3% |
| Xalabrands | $38.80M | $39.20M | $42.00M | $38.60M | $40.70M | $37.10M | $37.10M | $41.20M | $45.60M | $42.50M | $48.20M | $47.90M | 1.0% | -4.7% |
| Xanax | $38.10M | $34.80M | $39.50M | $34.20M | $33.90M | $32.30M | $36.50M | $38.60M | $35.40M | $34.50M | $35.10M | $28.20M | 1.0% | +12.4% |
| Complex GX and Biosimilars | – | – | – | – | – | – | – | – | – | – | – | $174.40M | – | – |
| Influvac | – | – | $63.60M | $125.40M | – | – | $52.70M | $121.30M | – | – | $54.90M | $137.20M | – | – |
By region
From the segment and revenue-disaggregation notes of Viatris's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.